Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF TECHNICAL OFFICER | February 25, 2025 | February 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,756 |
Ending reported balance
After 2025-02-27 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756 F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.
F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Feb 27, 2025 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 100 | $58.74 | $5,874.00 |
DisclosureSEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,756 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. Read SEC document |
| February 27, 2025 Filed Feb 27, 2025 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,597 | $58.25 | $93,028.44 |
DisclosureSEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,856 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F6 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 600 | $58.65 | $35,188.80 |
DisclosureSEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,453 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F5 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,400 | $58.09 | $546,055.40 |
DisclosureSEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,053 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 700 | $58.67 | $41,069.00 |
DisclosureSEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,453 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,300 | $58.01 | $539,465.10 |
DisclosureSEC source: 0001415889-25-005899 · form4-02272025_110233.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,153 F1 · kind: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 4,747 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005311 · form4-02242025_100257.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,238 Underlying: Common Stock · 4,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,410 | $57.75 | $139,177.50 |
DisclosureSEC source: 0001415889-25-005311 · form4-02242025_100257.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,453 F1 · shares: The reported disposition of 2,410 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 23, 2025 Filed Feb 24, 2025 22:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005311 · form4-02242025_100257.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 11,230 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005177 · form4-02212025_110206.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,230 Underlying: Common Stock · 11,230 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 23:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,902 | $0.00 Strike: $57.44 | $0.00 |
DisclosureSEC source: 0001415889-25-005177 · form4-02212025_110206.xml · derivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,902 Underlying: Common Stock · 11,902 shares Expires 2035-02-20 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 4,263 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 12 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,526 Underlying: Common Stock · 4,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,112 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 11 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,112 Underlying: Common Stock · 6,112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 20,891 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 10 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. F6 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,164 | $58.29 | $126,139.56 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 8 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,116 F4 · shares: The reported disposition of 2,164 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,103 | $58.29 | $180,873.87 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,017 F3 · shares: The reported disposition of 3,103 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 8,721 | $58.29 | $508,347.09 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,008 F2 · shares: The reported disposition of 8,721 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 3,386 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · derivative · entry 9 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,304 | $58.29 | $76,010.16 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,838 F1 · shares: The reported disposition of 1,304 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 15, 2025 Filed Feb 18, 2025 23:42 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004509 · form4-02182025_110228.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 20,342 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,342 Underlying: Common Stock · 20,342 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Unit · Derivative | 4,921 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,921 Underlying: Common Stock · 4,921 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 4,177 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,547 Underlying: Common Stock · 4,177 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 7,262 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004243 · form4-02142025_110258.xml · derivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,891 Underlying: Common Stock · 7,262 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2022 that included a performance measurement period ending December 31, 2024. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| October 16, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · derivative · entry 9 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,608 Underlying: Common Stock · 10,000 shares Expires 2030-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| October 16, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $53.26 | $532,590.00 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,756 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $52.88 to $53.60. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 16, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $19.98 | $199,800.00 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 4,491 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · derivative · entry 8 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,608 Underlying: Common Stock · 4,491 shares Expires 2030-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,509 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,352 Underlying: Common Stock · 5,509 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 77 | $54.25 | $4,176.87 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,756 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,923 | $53.74 | $533,291.79 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,833 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $53.24 to $54.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,491 | $19.98 | $89,730.18 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 22:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,509 | $16.65 | $91,724.85 |
DisclosureSEC source: 0001415889-24-025233 · form4-10162024_101045.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 22:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001415889-24-023657 · form4-09182024_100954.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,861 Underlying: Common Stock · 10,000 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 22:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,037 | $62.58 | $127,477.50 |
DisclosureSEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,756 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $62.41 to $62.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 22:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 7,963 | $61.89 | $492,838.03 |
DisclosureSEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,793 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $61.40 to $62.395. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 22:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $16.65 | $166,500.00 |
DisclosureSEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 22:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001415889-24-023657 · form4-09182024_100954.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,861 Underlying: Common Stock · 10,000 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F5 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 22:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $62.88 | $628,780.00 |
DisclosureSEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,756 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $62.585 to $63.275. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 22:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $16.65 | $166,500.00 |
DisclosureSEC source: 0001415889-24-023657 · form4-09182024_100954.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,580 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001415889-24-022363 · form4-08272024_110848.xml · derivative · entry 2 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,580 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 23:49 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,580 | $18.41 | $102,727.80 |
DisclosureSEC source: 0001415889-24-022363 · form4-08272024_110848.xml · nonDerivative · entry 1 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2024 Filed Aug 21, 2024 22:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001415889-24-021850 · form4-08212024_100827.xml · derivative · entry 7 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,861 Underlying: Common Stock · 10,000 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| August 21, 2024 Filed Aug 21, 2024 22:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 100 | $62.34 | $6,234.00 |
DisclosureSEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 5 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,176 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| August 21, 2024 Filed Aug 21, 2024 22:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,900 | $61.74 | $611,235.90 |
DisclosureSEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 4 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,276 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $61.325 to $62.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 21, 2024 Filed Aug 21, 2024 22:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $16.65 | $166,500.00 |
DisclosureSEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 3 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001415889-24-021850 · form4-08212024_100827.xml · derivative · entry 6 LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,861 Underlying: Common Stock · 10,000 shares Expires 2029-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. F4 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.